What the FDA labels say about taking them together
Quinapril and sacubitril/valsartan
Quinapril's FDA label of December 14, 2023 names sacubitril/valsartan in its contraindications section; sacubitril/valsartan's label does not name quinapril itself but warns about its class (ACE inhibitors). The quinapril label: “Do not administer quinapril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor.”
Check it at the source: the quinapril FDA label on DailyMed (effective December 14, 2023, Lupin Pharmaceuticals, Inc.); the sacubitril/valsartan FDA label on DailyMed (effective July 6, 2026, Novartis Pharmaceuticals Corporation).
What does the quinapril label say about sacubitril/valsartan?
Quinapril label, contraindicationsDo not administer quinapril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS and PRECAUTIONS ).
Source: FDA drug label (Quinapril), Lupin Pharmaceuticals, Inc., effective December 14, 2023 (SPL set 8ded0773-3aec-4e89-9836-d22a5a84abf0), via openFDA; the full label on DailyMed
What does the sacubitril/valsartan label say about quinapril?
Sacubitril/valsartan's label does not name quinapril itself; it warns about its class (ACE inhibitors):
Sacubitril/valsartan label, contraindicationsCONTRAINDICATIONS ENTRESTO is contraindicated: in patients with hypersensitivity to any component in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2)] with concomitant use of ACE inhibitors.
Sacubitril/valsartan label, drug interactionsBlockade of the Renin-Angiotensin-Aldosterone System Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4)].
Source: FDA drug label (ENTRESTO), Novartis Pharmaceuticals Corporation, effective July 6, 2026 (SPL set 000dc81d-ab91-450c-8eae-8eb74e72296f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Quinapril | Sacubitril/valsartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.533 per unit 49-51 mg |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once